Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: A pilot study

Breast Cancer Research and Treatment

Volumn 53, Issue 1, 1999, Pages 51-59

  Makris, Andreas ^a,e   Powles, T J ^a   Allred, D C ^b   Ashley, S E ^a   Trott, P A ^c   Ormerod, M G ^d   Titley, J C ^d   Dowsett, M ^c  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Bcl 2; Breast cancer; Estrogen receptor; FNA; Ki67; Neoadjuvant therapy; p53; Ploidy; Progesterone receptor; SPF

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN RECEPTOR; KI 67 ANTIGEN; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; BREAST CANCER; CELL CYCLE S PHASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOCYTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; PLOIDY; PRIORITY JOURNAL; QUANTITATIVE ASSAY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; METHOTREXATE; MIDDLE AGED; MITOXANTRONE; PILOT PROJECTS; PLOIDIES; PREOPERATIVE CARE; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033009647     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006179511178     Document Type: Article

References (40)

1. Powles TJ, Hickish TF, Makris A, Ashley SE, O'Brien MER, Tidy VA, Casey S, Nash AG, Sacks N, Cosgrove D, et al.: Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 13: 547-552, 1995
2. Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, Bartoli C, Coopmans de Yoldi G, Zucali R, Rilke F, et al.: Primary chemotherapy to avoid mastectomy in tumors with diameter of three centimeters or more. J Natl Cancer Inst 82: 1539-1545, 1990
3. Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, McNeese MD, Paulus D, Hug V, Holmes FA, Romsdahl MM, Fraschini G, et al.: Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62: 2507-2516, 1988
4. Scholl SM, Pierga JY, Asselain B, Beuzeboc P, Dorval T, Garcia-Giralt E, Jouve M, Palangie T, Remvikos Y, Durand JC, et al.: Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 31A(12): 1969-1975, 1996
5. Anderson EDC, Forrest APM, Levack PA, Chetty U, Hawkins RA: Response to endocrine manipulation and oestrogen receptor concentration in large operable breast cancer. Br J Cancer 60: 223, 1989
6. McGuire WL: The usefulness of steroid receptors in the management of primary and advanced breast cancer. In: Mouridson HT, Palshof T (eds): Breast Cancer: Experimental and Clinical Aspects. New York: Pergammon Press, 1980, pp. 39-43
7. Scottish Cancer Trials Breast Group and ICRF Breast Unit GH, London: Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish Trial. Lancet 341: 1293-1298, 1993
8. Howell A, Harland RNL, Barnes DM, Baildam AD, Wilkinson MJS, Hayward E, Swindell R, Sellwood RA: Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment. Cancer Res 47: 300-304, 1987
9. O'Reilly SM, Camplejohn RS, Rubens RD, Richards MA: DNA flow cytometry and response to preoperative chemotherapy for primary breast cancer. Eur J Cancer 28: 681-683, 1992
10. Remvikos Y, Jouve M, Beuzeboc B, Viehl P, Magdaelenat H, Pouillart P: Cell cycle modifications of breast cancers during neoadjuvant chemotherapy: a flow cytometry study on fine needle aspirates. Eur J Cancer 29A(13): 1843-1848, 1993
11. Ellis PA, Detre S, Burton SA, Salter J, Johnston SRD, Smith IE, Dowsett M: Changes in proliferation, apoptosis, and Bcl-2 in breast cancer specimens following neoadjuvant chemotherapy. Breast Cancer Res Treat 37 (suppl.): 36, 1996
12. Paradiso A, Tommasi S, Mangia A, Lorusso V, Simone G, De Lena M: Tumor-proliferative activity, progesterone receptor status, estrogen receptor level, and clinical outcome of estrogen receptor-positive advanced breast cancer. Cancer Research 50: 2958-2962, 1990
13. Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993
14. Reed JC: Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Current Opinion in Oncology 7: 541-546, 1995
15. Montes A, Powles TJ, O'Brien MER, Ashley SE, Luckitt J, Treleavan J: A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome. Eur J Cancer 29A: 1854-1857, 1993
16. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD: Assessment of response to therapy in advanced breast cancer. Br J Cancer 35: 292-298, 1977
17. Walker KJ, Bouzubar N, Robertson J, Ellis IO, Elston CW, Blamey RW, Wilson DW, Griffiths K, Nicholson RI: Immunocytochemical localization of estrogen receptor in human breast tissue. Cancer Res 48: 6517-6522, 1988
18. Allred DC, Bustamante MA, Daniel CO, Gaskill HV, Cruz AB: Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Arch Surg 125: 107-113, 1990
19. Ormerod MG (ed): Flow cytometry. A practical approach. 2nd edition. Oxford University Press, Oxford, 1994
20. Makris A, Powles TJ, Dowsett M, Osborne CK, Trott PA, Fernando IN, Ashley SE, Ormerod MG, Titley JC, Gregory RK, et al.: Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clinical Cancer Research 3: 593-600, 1997
21. Makris A, Allred DC, Powles TJ, Dowsett M, Fernando IN, Trott PA, Ashley SE, Ormerod MG, Titley JC, Osborne CK: Cytological evaluation of biological prognostic markers from primary breast carcinomas. Breast Cancer Res Treat 44: 65-74, 1997
22. Fernando IN, Titley JC, Powles TJ, Dowsett M, Trott PA, Ashley SE, Ford HT, Ormerod MG: Measurement of S-phase fraction and ploidy in sequential fine-needle aspirates from primary human breast tumours treated with tamoxifen. Br J Cancer 70: 1211-1216, 1994
23. Prey MU, Meyer JS, Stone KR. Heterogeneity of breast carcinomas determined by flow cytometric analysis. J Surg Oncol 29: 35-39, 1985
24. Remvikos Y, Vielh P, Padoy E, et al.: Breast cancer proliferation measured on cytological samples: a study by flow cytometry of S-phase fractions and BrdU incorporation. Br J Cancer 64: 501-507, 1991
25. Osborne CK, Boldt DH, Estrada P: Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. Cancer Res 44: 1433-1439, 1984
26. Osborne CK, Boldt CH, Clark GM, Trent JM: Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res 43: 3583-3585, 1983
27. Sarkaria JN, Gibson DFC, Jordan VC, et al.: Tamoxifen-induced increase in the potential doubling time of MCF-7 xenografts as determined by bromodeoxyuridine labeling and flow cytometry. Cancer Research 53: 4413-4417, 1993
28. Osborne CK, Hobbs K, Clark GM: Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 45: 584-590, 1985
29. Clarke RB, Laidlaw IJ, Jones LJ, Howell A, Anderson E: Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. Br J Cancer 67: 606-611, 1993
30. Johnston SRD, MacLennan KA, Sacks NPM, Salter J, Smith IE, Dowsett M: Modulation of Bcl-2 and Ki67 expression in oestrogen-receptor-positive human breast cancer by tamoxifen. Eur J Cancer 30A(11): 1663-1669, 1995
31. Rasbridge SA, Gillet CE, Seymour A-M, Patel K, Richards MA, Rubens RD, Millis RR: The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer 70: 335-341, 1994
32. Billgren A, Rutqvist LE, Skoog L, Wilking N: Changes of proliferating fraction during neoadjuvant chemotherapy of primary breast cancer as a predictor of objective response. Breast Cancer Research and Treatment 32 (suppl.): 63, 1994
33. Gardin G, Alama A, Rosso R, Campora E, Repetto L, Merlini L, Naso C, Camoriano A, Meazza R, Barbieri F, et al.: Relationship of variations in tumor cell kinetics induced by primary chemotherapy to tumor regression and prognosis in locally advanced breast cancer. Breast Cancer Res Treat 32: 311-318, 1994
34. Gorczyca W, Tuziak T, Kram A, Melamed MR, Darzynkiewicz Z: Detection of apoptosis-associated DNA strand breaks in fine-needle aspiration biopsies by in situ end labeling of fragmented DNA. Cytometry 15: 169-175, 1994
35. Ellis PA, Smith IE, Salter J, Detre S, O'Brien MER, Ramage F, Dowsett M: Pre-operative/neoadjuvant chemotherapy for early breast cancer induces apoptosis. Proc Annu Meet Am Soc Clin Oncol 15: 112, 1996
36. Skoog L, Rutqvist LE, Wilking N: Analysis of hormone receptors and proliferation fraction in fine-needle aspirates from primary breast carcinomas during chemotherapy or tamoxifen treatment. Acta Oncologica 31(2): 139-141, 1992
37. Lane DP: p53 and human cancers. British Medical Bulletin 50(3): 582-599, 1994
38. Dive C, Evans CA, Whetton AD: Induction of apoptosis - new targets for cancer chemotherapy. Semin Cancer Biol 3: 417-427, 1992
39. Wallon MI, Whysong D, O'Connor PM, Hockenbery D, Korsmeyer SJ, Kohn KW: Constitutive expression of human bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res 53: 1853-1861, 1993
40. Ohmori T, Podack ER, Nishio K: Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem Biophys Res Commun 192: 30-36, 1993